Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.50    -2.00 (-2.84%)
Bid:
68.00
Ask:
69.00
Spread: 1.00 (1.471%)
Market Cap: £320.96m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directors Dealings

24 Feb 2014 07:00

RNS Number : 6954A
Avacta Group PLC
24 February 2014
 

24 February 2014

Avacta Group plc

("Avacta" or the "Group")

 

Directors' Dealings

 

The Group announces the following changes to the equity incentives of its Non-Executive Chairman, Trevor Nicholls, and its Chief Operating Officer, Craig Slater.

 

Trevor Nicholls

On his appointment to the Board of Avacta on 2 August 2013, Dr Nicholls was awarded options over 5,454,545 ordinary shares of 0.1p each in the Group ("Ordinary Shares"). In order to pursue best corporate governance practice, the Avacta Board has agreed with Dr Nicholls that 3,500,000 of those options should vest conditional upon Dr Nicholls exercising those options immediately and conditional upon it being agreed by Dr Nicholls that the balance of 1,954,545 options over Ordinary Shares be cancelled with immediate effect. Dr Nicholls has agreed to that conditionality and therefore the options over 3,500,000 Ordinary Shares have vested and Dr Nicholls has exercised his option over those Ordinary Shares. 

 

The exercise price of each option is 0.55 pence per share and, following exercise, Dr Nicholls is now interested in a total of 3,500,000 ordinary shares of 0.1p each in the Group, representing approximately 0.1% of the Group's issued share capital.

 

Dr Nicholls no longer holds any options over ordinary shares in Avacta.

 

Application will be made for the 3,500,000 new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 28 February 2014.

 

The total number of Ordinary Shares in issue following the above issue will be 4,026,051,956 each with voting rights. No Ordinary Shares are held in Treasury.

 

The above figure of 4,026,051,956 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the FCA's Disclosure and Transparency Rules.

 

Craig Slater

On 21 February 2014, Mr Slater was granted options over 20,000,000 Ordinary Shares pursuant to the Avacta Group Enterprise Management Incentive ("EMI") Scheme. The option exercise price is 1.18p per share and the options vest as follows:

 

- 5,000,000 options over Ordinary Shares vest on 23 December 2014

- 5,000,000 options over Ordinary Shares vest on 23 December 2015

- 5,000,000 options over Ordinary Shares vest on 23 December 2016

- 5,000,000 options over Ordinary Shares vest on 23 December 2017

 

In addition, on 21 February 2014 Mr Slater purchased an interest in 34,082,086 existing Ordinary Shares at a price of 1% of 1.18 pence per share, in accordance with the terms of the Avacta Joint Share Ownership Plan (the "Joint Share Ownership Plan") established on 9 January 2012. This interest is joint with Avacta Group Trustee Limited as trustee for the Avacta Group Employee's Share Trust under the Joint Share Ownership Plan. Following this purchase, Mr Slater has an interest in 34,082,086 Ordinary shares, representing approximately 0.8% of the Group's issued share capital.

 

 

Enquiries:

 

Avacta Group plc

Tel: +44 (0) 844 414 0452

Alastair Smith, Chief Executive Officer

www.avacta.com

Tim Sykes, Chief Financial Officer

Numis Securities Limited

Tel: +44 (0) 207 260 1000

Michael Meade / Freddie Barnfield - Nominated Adviser

www.numiscorp.com

James Black - Corporate Broking

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLFFSLFRILFIS
Date   Source Headline
24th Jun 20207:00 amRNSUpdate on COVID-19 Test Development Partnership
22nd Jun 20202:52 pmRNSResult of AGM
18th Jun 20207:00 amRNSUpdate on Affimer® Therapy for COVID-19 Infection
17th Jun 202011:05 amRNSSecond Price Monitoring Extn
17th Jun 202011:00 amRNSPrice Monitoring Extension
15th Jun 20204:41 pmRNSSecond Price Monitoring Extn
15th Jun 20204:36 pmRNSPrice Monitoring Extension
15th Jun 20202:05 pmRNSSecond Price Monitoring Extn
15th Jun 20202:00 pmRNSPrice Monitoring Extension
15th Jun 202011:05 amRNSSecond Price Monitoring Extn
15th Jun 202011:00 amRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20206:35 pmRNSHolding(s) in Company
9th Jun 20207:01 amRNSInvestor Presentation
9th Jun 20207:00 amRNSUpdate on COVID-19 Test Development with Adeptrix
8th Jun 20204:15 pmRNSPosting of Circular and Notice of General Meeting
4th Jun 20205:16 pmRNSDirector/PDMR Shareholding
4th Jun 20205:15 pmRNSResult of Fundraising
4th Jun 202012:30 pmRNSIncrease in Fundraising
4th Jun 202011:05 amRNSSecond Price Monitoring Extn
4th Jun 202011:00 amRNSPrice Monitoring Extension
4th Jun 20209:05 amRNSSecond Price Monitoring Extn
4th Jun 20209:00 amRNSPrice Monitoring Extension
4th Jun 20207:01 amRNSPrimaryBid.com Offers
4th Jun 20207:00 amRNSProposed Fundraising to raise up to £45 million
28th May 20207:00 amRNSPosting of Annual Report and Notice of AGM
26th May 202011:05 amRNSSecond Price Monitoring Extn
26th May 202011:00 amRNSPrice Monitoring Extension
26th May 20208:06 amRNSIssue of Equity
21st May 20202:05 pmRNSSecond Price Monitoring Extn
21st May 20202:00 pmRNSPrice Monitoring Extension
20th May 20207:00 amRNSDistribution Agreement for COVID-19 Antigen Test
15th May 20204:41 pmRNSSecond Price Monitoring Extn
15th May 20204:35 pmRNSPrice Monitoring Extension
15th May 20202:06 pmRNSSecond Price Monitoring Extn
15th May 20202:00 pmRNSPrice Monitoring Extension
15th May 202011:06 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
15th May 20209:30 amRNSIssue of Equity
15th May 20207:00 amRNSSARS-COV-2 Neutralising Affimers
11th May 20207:00 amRNSAvacta Ships SARS-COV-2 Affimer Reagents
6th May 20207:00 amRNSResults for the period ending 31 December 2019
5th May 20206:15 pmRNSHolding(s) in Company
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSCOVID-19 Antigen Test Collaboration with Adeptrix
27th Apr 20205:30 pmRNSHolding(s) in Company
27th Apr 20205:00 pmRNSHolding(s) in Company
24th Apr 20206:00 pmRNSHolding(s) in Company
24th Apr 20204:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.